An Ozarks doctor recently returned from presenting at a major international Alzheimer’s disease conference in Vienna, Austria ...

Mayo Clinic researchers are studying why some Alzheimer's patients decline rapidly, aiming to find causes, biomarkers, and ...

NU-9 targets a shared underlying mechanism found in various neurodegenerative diseases. A new study from Northwestern ...

Founder of Inspire Napa Valley Kerrin Laz joined host Rachael Maurer to chat about how they are bringing wine and ...

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias.

Key takeaways Cholesterol regulation and neuronal vulnerability: The study found that neurons in the locus coeruleus (LC)—a ...

"So we're playing politics with funding that's supposed to currently be going to Alzheimer's victims, stroke victims, ...

A new scientific breakthrough may soon offer hope for people affected by Alzheimer’s disease. A group of researchers in Spain ...

European regulators have finally approved the Alzheimer’s treatment Leqembi after an advisory committee initially rejected the drug last summer.

Hilary Evans-Newton is the Chief Executive of Alzheimer’s Research UK. Hilary joined Alzheimer’s Research UK in 2013 and has overseen significant growth in income in recent years, which has ...

Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved ...

Advocates will rally in Carson City, Nevada on Wednesday for greater support for dementia patients and their families. More ...